Background: Schistosomal cor pulmonale is considered an important pathological condition in endemic areas. Few recent studies have reported the role of apoptosis in pulmonary hypertension. Objectives: The aim of this study was to assess serum levels of soluble Fas (sFas), an inhibitor of apoptosis, in patients with schistosomal cor pulmonale as compared to patients with cor pulmonale due to chronic obstructive pulmonary disease (COPD) and normal subjects. Methods: Serum sFas was assessed in 15 men with schistosomal cor pulmonale (age 32 ± 10 years), 15 men with chronic cor pulmonale secondary to COPD and 20 healthy men, matched for age. Results: Serum levels of sFas were significantly higher in patients with schistosomal cor pulmonale (74 ± 80 U/ml) than in patients with cor pulmonale due to COPD (15 ± 10 U/ml) and normal subjects (19 ± 11 U/ml, p < 0.001 in both). In patients with schistosomal cor pulmonale, sFas was significantly higher in patients with mean pulmonary artery pressure >30 mm Hg as compared to patients with pressure ≤30 mm Hg (109 ± 97 vs. 34 ± 20 U/ml, p = 0.01). There was a significant correlation between serum sFas and the mean pulmonary artery pressure in patients with bilharzial cor pulmonale (r = 0.4, p < 0.01), but not in patients with COPD (r = 0.1, p = NS). Conclusions: Serum sFas levels are elevated in patients with schistosomal cor pulmonale and they are related to the severity of pulmonary hypertension. These findings suggest a role of apoptosis in schistosomal cor pulmonale.

Keywords:
Pulmonary hypertension, Schistosomal cor pulmonale, Apoptosis, Fas
1.
Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF: The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001;22:405–418.
2.
Cheng J, Zohon T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by soluble form of the Fas molecule. Science 1994;263:1759–1762.
3.
Thompson C: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456–1462.
4.
Steller H: Mechanisms and genes of cellular suicide. Science 1995;267:1445–1449.
5.
James T: Normal and abnormal consequences of apoptosis in the human heart: From postnatal morphogenesis to paroxysmal arrhythmia. Circulation 1994;90:556–573.
6.
Bennett MR: Apoptosis in the cardiovascular system. Heart 2002;87:480–487.
7.
Grodzicky T, Elkon KB: Apoptosis in rheumatic diseases. Am J Med 2000;108:73–82.
8.
James TN: Apoptosis in cardiac disease (review). Am J Med 1999;107:606–620.
9.
Bethlem EP, Schettino Gde P, Carvalho CR: Pulmonary schistosomiasis. Curr Opin Pulm Med 1997;3:361–365.
10.
Morris W, Knauer CM: Cardiopulmonary manifestations of schistosomiasis (review). Semin Respir Infect 1997;12:159–170.
11.
Andrade Z, Andrade S: Pathogenesis of schistosomal pulmonary arteritis. Am J Trop Med Hyg 1970;19:305–310.
12.
Sadigursky M, Andrade ZA: Pulmonary changes in schistosomal cor pulmonale. Am J Trop Med Hyg 1982;31:779–784.
13.
Rabinovitch M: Pathobiology of pulmonary hypertension. Extracellular matrix. Clin Chest Med 2001;22:433–449.
14.
Jones P, Rabinovitch M: Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 1996;79:1131–1142.
15.
Jones P, Cowan K, Rabinovitch M: Tenascin C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997;150:1349–1360.
16.
American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:2242–2244.
17.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358–367.
18.
Yock PG, Popp RL: Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657–662.
19.
Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E: Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359–365.
20.
Yue TL, Ohlstein EH, Ruffolo RR Jr: Apoptosis: A potential target for discovering novel therapies for cardiovascular diseases. Curr Opin Chem Biol 1999;3:474–480.
21.
Thompson CB: Apoptosis in the pathogenesis and treatment of disease (review). Science 1995;267:1456–1462.
22.
Naeije R, Barbera JA: Pulmonary hypertension associated with COPD. Crit Care 2001;5:286–289.
23.
Majo J, Ghezzo H, Cosio MG: Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001;17:946–953.
24.
Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311–1319.
25.
Kasahara Y, Tuder RM, Cool CD, Voelkel NF: Expression of 15-lipoxygenase and evidence for apoptosis in the lungs from patients with COPD. Chest 2000;117(suppl 1):260S.
26.
Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nomura M, Ohno A, Watanabe M, Sano H, Kumada H, Sawa T, Fujiwara H: An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998;92:993–999.
27.
Takabatake N, Nakamura H, Inoue S, Terashita K, Yuki H, Kato S, Yasumura S, Tomoike H: Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med 2000;94:1215–1220.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.